Vertex Pharmaceuticals Incorporated (LON:0QZU)
London
· Delayed Price · Currency is GBP · Price in USD 393.58
+10.85 (2.84%)
At close: Aug 13, 2025
Vertex Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 3,638 | -535.6 | 3,620 | 3,322 | 2,342 | 2,712 | Upgrade
|
| Depreciation & Amortization | 174.6 | 182 | 169.5 | 148.3 | 125.6 | 109.5 | Upgrade
|
| Other Amortization | 25.2 | 25.2 | 11.8 | - | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 379 | - | - | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 27.6 | 57.7 | 0.6 | 149.1 | -17.1 | -311.9 | Upgrade
|
| Stock-Based Compensation | 685.8 | 698.5 | 581.2 | 491.3 | 441.4 | 429.5 | Upgrade
|
| Other Operating Activities | -279.8 | -405.6 | -579.7 | -321.6 | -143.3 | 369.1 | Upgrade
|
| Change in Accounts Receivable | -170.8 | -99.3 | -84.1 | -358.6 | -274.7 | -223.4 | Upgrade
|
| Change in Inventory | -645.7 | -517.3 | -322.9 | -136.4 | -92.8 | -132 | Upgrade
|
| Change in Accounts Payable | 108.3 | 49.5 | 48.7 | 120.8 | 31.9 | 51.3 | Upgrade
|
| Change in Other Net Operating Assets | -95.4 | 52.3 | 92.6 | 715 | 230.4 | 249.7 | Upgrade
|
| Operating Cash Flow | 3,846 | -492.6 | 3,537 | 4,130 | 2,644 | 3,254 | Upgrade
|
| Operating Cash Flow Growth | - | - | -14.35% | 56.23% | -18.75% | 107.32% | Upgrade
|
| Capital Expenditures | -346.7 | -297.7 | -200.4 | -204.7 | -235 | -259.8 | Upgrade
|
| Cash Acquisitions | - | - | - | -295.9 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | - | -187.7 | -58 | - | - | - | Upgrade
|
| Investment in Securities | -1,315 | -3,231 | -2,852 | 227.3 | -105.9 | 359.2 | Upgrade
|
| Other Investing Activities | -48.6 | -54 | -31 | -47.8 | - | - | Upgrade
|
| Investing Cash Flow | -1,710 | -3,770 | -3,142 | -321.1 | -340.9 | 99.4 | Upgrade
|
| Long-Term Debt Issued | - | - | - | - | 28.3 | 13.3 | Upgrade
|
| Total Debt Issued | - | - | - | - | 28.3 | 13.3 | Upgrade
|
| Long-Term Debt Repaid | - | -33.6 | -44.9 | -85.5 | -47 | -42.3 | Upgrade
|
| Total Debt Repaid | -9.3 | -33.6 | -44.9 | -85.5 | -47 | -42.3 | Upgrade
|
| Net Debt Issued (Repaid) | -9.3 | -33.6 | -44.9 | -85.5 | -18.7 | -29 | Upgrade
|
| Issuance of Common Stock | 108.5 | 114.6 | 134.6 | 186.3 | 102 | 264.9 | Upgrade
|
| Repurchase of Common Stock | -1,911 | -1,582 | -653.7 | -172 | -1,561 | -739.4 | Upgrade
|
| Other Financing Activities | 3.3 | 6.2 | 1.8 | 3.5 | - | -1.8 | Upgrade
|
| Financing Cash Flow | -1,808 | -1,495 | -562.2 | -67.7 | -1,478 | -505.3 | Upgrade
|
| Foreign Exchange Rate Adjustments | 63.2 | -42.6 | 26.9 | -29.2 | -13.4 | 20.6 | Upgrade
|
| Net Cash Flow | 391 | -5,800 | -139.7 | 3,712 | 811.2 | 2,868 | Upgrade
|
| Free Cash Flow | 3,500 | -790.3 | 3,337 | 3,925 | 2,409 | 2,994 | Upgrade
|
| Free Cash Flow Growth | - | - | -14.99% | 62.97% | -19.55% | 100.39% | Upgrade
|
| Free Cash Flow Margin | 30.65% | -7.17% | 33.81% | 43.95% | 31.80% | 48.24% | Upgrade
|
| Free Cash Flow Per Share | 13.54 | -3.06 | 12.81 | 15.15 | 9.27 | 11.37 | Upgrade
|
| Cash Interest Paid | 17 | 30.5 | 43.1 | 52.3 | 56.3 | 54.5 | Upgrade
|
| Cash Income Tax Paid | 1,248 | 1,082 | 1,677 | 1,058 | 476.3 | 191.8 | Upgrade
|
| Levered Free Cash Flow | 2,915 | 2,726 | 3,510 | 3,307 | 2,402 | 2,232 | Upgrade
|
| Unlevered Free Cash Flow | 2,925 | 2,745 | 3,538 | 3,342 | 2,441 | 2,268 | Upgrade
|
| Change in Working Capital | -803.6 | -514.8 | -265.7 | 340.8 | -105.2 | -54.4 | Upgrade
|
Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.